These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34120765)

  • 1. Cost effectiveness of typhoid vaccination in India.
    Chauhan AS; Kapoor I; Rana SK; Kumar D; Gupta M; John J; Kang G; Prinja S
    Vaccine; 2021 Jul; 39(30):4089-4098. PubMed ID: 34120765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Date K; Shimpi R; Luby S; N R; Haldar P; Katkar A; Wannemuehler K; Mogasale V; Pallas S; Song D; Kunwar A; Loharikar A; Yewale V; Ahmed D; Horng L; Wilhelm E; Bahl S; Harvey P; Dutta S; Bhatnagar P
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S172-S178. PubMed ID: 32725235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
    Ryckman T; Karthikeyan AS; Kumar D; Cao Y; Kang G; Goldhaber-Fiebert JD; John J; Lo NC; Andrews JR
    J Infect Dis; 2021 Nov; 224(Supple 5):S612-S624. PubMed ID: 35238367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.
    Antillón M; Bilcke J; Paltiel AD; Pitzer VE
    Vaccine; 2017 Jun; 35(27):3506-3514. PubMed ID: 28527687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
    Debellut F; Mkisi R; Masoo V; Chisema M; Mwagomba D; Mtenje M; Limani F; Mategula D; Zimba B; Pecenka C
    Vaccine; 2022 Mar; 40(12):1741-1746. PubMed ID: 35153097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.
    Mogasale V; Ramani E; Park IY; Lee JS
    Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Burrows H; Antillón M; Gauld JS; Kim JH; Mogasale V; Ryckman T; Andrews JR; Lo NC; Pitzer VE
    Vaccine; 2023 Jan; 41(4):965-975. PubMed ID: 36586741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
    Longley AT; Date K; Luby SP; Bhatnagar P; Bentsi-Enchill AD; Goyal V; Shimpi R; Katkar A; Yewale V; Jayaprasad N; Horng L; Kunwar A; Harvey P; Haldar P; Dutta S; Gidudu JF
    Clin Infect Dis; 2021 Aug; 73(4):e927-e933. PubMed ID: 33502453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?
    Steele AD; Carey ME; Kumar S; MacLennan CA; Ma LF; Diaz Z; Zaidi AKM
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S185-S190. PubMed ID: 32725223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.
    Phillips MT; Antillon M; Bilcke J; Bar-Zeev N; Limani F; Debellut F; Pecenka C; Neuzil KM; Gordon MA; Thindwa D; Paltiel AD; Yaesoubi R; Pitzer VE
    BMC Infect Dis; 2023 Mar; 23(1):143. PubMed ID: 36890448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for Typhoid Vaccination in India.
    Srinivasan M; Sindhu KN; John J; Kang G
    Indian Pediatr; 2019 Jun; 56(6):453-458. PubMed ID: 31278221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.
    Shakya M; Neuzil KM; Pollard AJ
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S770-S774. PubMed ID: 34374785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
    Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for preventing typhoid fever.
    Milligan R; Paul M; Richardson M; Neuberger A
    Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy.
    Bahl R; Sinha A; Poulos C; Whittington D; Sazawal S; Kumar R; Mahalanabis D; Acosta CJ; Clemens JD; Bhan MK
    J Health Popul Nutr; 2004 Sep; 22(3):304-10. PubMed ID: 15609783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.